同源康

ABOUT

TYK Medicines Focus on new drug research and development
Together, we search for the cure.

Discover More

NEWS

TYK Medicines, Inc.’s EGFR-Targeted Innovative Drug Asandeutertinib Demonstrates Excellent Efficacy in NSCLC Patients with Brain Metastases — Interim Results from the ESAONA Pivotal Study Announced at WCLC 2025

Asandeutertinib (TY-9591) Submitted for Pre-New Drug Application

JTO Published Phase I Study Results of Asandeutertinib Mesylate Tablets

RESEARCH

An innovative biotechnology company focusing on the research and development of innovative drugs